Closing Thoughts on Hypoparathyroidism Management

In the final episode, ‘Closing Thoughts on Hypoparathyroidism Management,’ the panelists share their key takeaways from the series discussion on hypoparathyroidism.

Led by the moderator, Dr. Kohlmeier, the panelists, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, emphasize that PTH-based therapy marks a shift toward physiologic therapy beyond calcium supplementation. They also stress that chronic hypoparathyroidism is a lifelong, multisystem disease requiring individualized care and ongoing research. The panel highlight the need for clear communication with providers, vigilant safety practices, and a medical advocate when possible. Lastly, they describe the era as exciting, noting that meaningful treatment options, such as palopegteriparatide and others in development, will enable truly personalized management plans. Their insights underscore the importance of integrating emerging therapies with comprehensive monitoring to optimize patient outcomes significantly.

Thank you for watching this HCPLive Peer Exchange series on hypoparathyroidism. Please subscribe to our newsletter for information on upcoming video series.